Gene therapy aims to calm overactive bladder for years with one shot

NCT ID NCT07227285

Not yet recruiting Disease control Sponsor: EG 427 Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study follows 16 people who already received EG110A, a gene therapy that uses a modified herpes virus to deliver a botulinum toxin-like protein to relax bladder muscles. Researchers will track side effects and how well the treatment works over five years. The goal is to see if a single injection can safely control overactive bladder caused by spinal cord injury.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: EG110A (a gene therapy using a modified herpes virus to deliver botulinum toxin light chain)
What this could lead to: If successful, this could show that a single dose of EG110A safely controls overactive bladder symptoms for years, reducing the need for repeated treatments.
What could go wrong: This is an early-phase, small study (16 people) focused on safety, not proof of effectiveness. Gene therapies can have unexpected long-term side effects, and the virus-based delivery may cause immune reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SPINAL CORD INJURY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

overactive bladder spinal cord injury

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SPINAL CORD INJURY URINARY BLADDER OVERACTIVE

Contacts and locations

Locations

Rancho Los Amigos National Rehabilitation Center

Downey, California, 90242, United States
Sidney Kimmel Medical College

Philadelphia, Pennsylvania, 19107, United States
UTHealth Houston / TIRR Memorial Hermann

Houston, Texas, 77030, United States
University of Michigan Rogel Cancer Center

Ann Arbor, Michigan, 48109, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.